Ensign Peak Advisors
VTVT icon

Ensign Peak Advisors’s vTv Therapeutics VTVT Stock Holding History

Ensign Peak Advisors’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-8,057
Closed -$909K – 1858
2021
Q1 		$909K Buy
8,057
+3,354
+71% +$330K ﹤0.01% 1451
2020
Q4 		$350K Buy
+4,703
New +$361K ﹤0.01% 1656

Other funds holding VTVT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WAG
Winthrop Advisory Group Boston, Massachusetts $1.48B AUM 22.62% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CIM
CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ensign Peak Advisors's VTVT Position: Q2 2021 in Review

Ensign Peak Advisors sold out of vTv Therapeutics (VTVT) in Q2 2021, closing a stake of 8,057 shares — an estimated $909K sold.

Ensign Peak Advisors first reported a position in VTVT in Q4 2020 and held it in 2 quarters. The position peaked at $909K in Q1 2021. 42 funds tracked by Wall St. Rank hold VTVT as of Q2 2021.

  • Ensign Peak Advisors reported no remaining vTv Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Ensign Peak Advisors sold 8,057 vTv Therapeutics shares in Q2 2021, an estimated $909K.
  • Ensign Peak Advisors first reported a position in vTv Therapeutics in Q4 2020 and held it in 2 quarters.
  • Ensign Peak Advisors's vTv Therapeutics position peaked at $909K in Q1 2021.
  • 42 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2021.

Based on Ensign Peak Advisors's 13F filing for Q2 2021, filed 13 Aug 2021.